Physician profile
Stephen D Ward
NPI 1215964184
$1,061.60
in general payments reported to CMS, 2019-2025
18 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $153 · 2021: $118 · 2022: $221 · 2023: $94.41 · 2024: $181 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.99 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $185.87 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $147.71 | 2019-2025 | Cequa |
| Alcon Vision LLC | $138.77 | 2019-2025 | Clareon |
| Thea Pharma INC. | $120.67 | 2023-2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $99.43 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $63.78 | 2020-2022 | |
| Abbvie INC. | $50.51 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $41.04 | 2023 | Vyzulta, Miebo |
| Oyster Point Pharma, INC. | $36.82 | 2023-2024 | Tyrvaya |
| Harrow Eye, LLC | $32.07 | 2024-2025 | Vevye |
| Smith+Nephew, INC. | $26.32 | 2022 | |
| Kala Pharmaceuticals, INC. | $22.32 | 2022 | |
| Akorn Operating Company LLC | $22.21 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.51 | 2020 | |
| Shire North American Group INC | $18.44 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.68 | 2020 | |
| Eyevance Pharmaceuticals LLC | $12.46 | 2022 | |
| Horizon Therapeutics Plc | $11.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.